114 related articles for article (PubMed ID: 38888865)
1. Association Between Cost-Sharing and Buprenorphine Prescription Abandonment.
Chua KP; Conti RM; Lagisetty P; Bohnert ASB; Nuliyalu U; Nguyen TD
J Gen Intern Med; 2024 Jun; ():. PubMed ID: 38888865
[TBL] [Abstract][Full Text] [Related]
2. Association Between Cost Sharing and Naloxone Prescription Dispensing.
Chua KP; Conti RM; Lagisetty P; Bohnert AS; He S; Nguyen TD
JAMA; 2024 Jun; ():. PubMed ID: 38869887
[TBL] [Abstract][Full Text] [Related]
3. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.
Nguyen T; Ziedan E; Simon K; Miles J; Crystal S; Samples H; Gupta S
JAMA Netw Open; 2022 Jun; 5(6):e2214765. PubMed ID: 35648400
[TBL] [Abstract][Full Text] [Related]
5. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP38-44. PubMed ID: 21711076
[TBL] [Abstract][Full Text] [Related]
6. The epidemiology of prescriptions abandoned at the pharmacy.
Shrank WH; Choudhry NK; Fischer MA; Avorn J; Powell M; Schneeweiss S; Liberman JN; Dollear T; Brennan TA; Brookhart MA
Ann Intern Med; 2010 Nov; 153(10):633-40. PubMed ID: 21079218
[TBL] [Abstract][Full Text] [Related]
7. Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV.
Johnston SS; Juday T; Seekins D; Espindle D; Chu BC
J Manag Care Pharm; 2012 Mar; 18(2):129-45. PubMed ID: 22380472
[TBL] [Abstract][Full Text] [Related]
8. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
J Oncol Pract; 2011 May; 7(3 Suppl):46s-51s. PubMed ID: 21886519
[TBL] [Abstract][Full Text] [Related]
9. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
Mark TL; Parish WJ; Zarkin GA
JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
[TBL] [Abstract][Full Text] [Related]
10. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020.
Strahan AE; Desai S; Zhang K; Guy GP
JAMA Netw Open; 2023 Feb; 6(2):e2254590. PubMed ID: 36763363
[TBL] [Abstract][Full Text] [Related]
11. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
12. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
[TBL] [Abstract][Full Text] [Related]
13. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
[TBL] [Abstract][Full Text] [Related]
14. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
Kaur AD; McQueen A; Jan S
J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
[TBL] [Abstract][Full Text] [Related]
15. Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines.
Wong WB; Donahue A; Thiesen J; Yeaw J
J Manag Care Spec Pharm; 2023 Mar; 29(3):324-334. PubMed ID: 36692908
[No Abstract] [Full Text] [Related]
16. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
[TBL] [Abstract][Full Text] [Related]
17. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
18. Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019.
Ijioma SC; Chilcoat HD; DeVeaugh-Geiss AM
J Subst Use Addict Treat; 2023 Apr; 147():208980. PubMed ID: 36841074
[TBL] [Abstract][Full Text] [Related]
19. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
Saloner B; Levin J; Chang HY; Jones C; Alexander GC
JAMA Netw Open; 2018 Aug; 1(4):e181588. PubMed ID: 30646116
[TBL] [Abstract][Full Text] [Related]
20. Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies.
Freeman PR; Hammerslag LR; Ahrens KA; Sharbaugh M; Gordon AJ; Austin AE; Donohue JM; Allen LD; Barnes AJ; Talbert JC
JAMA Health Forum; 2024 May; 5(5):e241077. PubMed ID: 38758569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
